PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 31, 2023 -- Presurgical 68Ga-prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves prediction of biochemical recurrence-free survival (BCR-FS) for patients with intermediate- to high-risk prostate cancer, according to a study published online July 21 in European Urology.
Loïc Djaïleb, M.D., Ph.D., from the David Geffen School of Medicine at the University of California Los Angeles, and colleagues conducted a follow-up study of a surgical cohort assessed in a prospective phase 3 imaging trial involving 277 patients with intermediate- to high-risk prostate cancer treated with radical prostatectomy and pelvic lymph node dissection. The added prognostic value of presurgical PSMA-PET for BCR-FS compared to the presurgical Cancer of the Prostate Risk Assessment (CAPRA) and postsurgical CAPRA-Surgery (CAPRA-S) scores was assessed.
Patients were followed for a median of 32.4 months after surgery; clinical follow-up was available for 240 patients. The researchers found that 91 of 240 BCR events were observed (38 percent). In 17 percent of patients, PSMA-PET extraprostatic disease (N1/M1) was found. Significant univariate predictors of BCR included PSMA-PET prostate uptake, PSMA-PET N1/M1, and CAPRA and CAPRA-S scores. The risk assessment for BCR was significantly improved with the addition of PSMA-PET N1/M1 status to the presurgical CAPRA score compared with the presurgical CAPRA score alone (C-statistic, 0.70 versus 0.63). There was no significant difference observed for the C-index of the postsurgical model utilizing the postsurgical CAPRA-S score alone from the presurgical model combining the presurgical CAPRA score and PSMA-PET N1/M1 status.
"In patients with prostate cancer considered for surgery, PSMA PET can provide information on the risk of recurrence after surgery, before the surgery even happens," Djaïleb said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer
FRIDAY, May 31, 2024 -- Active surveillance is an effective management strategy for men with favorable-risk prostate cancer, with an estimated rate of metastasis of 1.4 percent at...
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...
Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income
FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.